Beta Lactam and Beta Lactamase Inhibitors Market Size, Share, Trends, Growth and Forecast 2032

According to the report published by Zion Market Research, the global Beta Lactam and Beta Lactamase Inhibitors Market size was valued at USD 28.76 Billion in 2023 and is predicted to reach USD 34.77 Billion by the end of 2032. The market is expected to grow with a CAGR of 2.4% during the forecast period. The report analyzes the global Beta Lactam and Beta Lactamase Inhibitors Market’s growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Beta Lactam and Beta Lactamase Inhibitors Market industry.

Global Beta Lactam and Beta Lactamase Inhibitors Market: Overview

Beta-lactam and beta-lactamase inhibitors are natural, semi-synthetic, or synthetic chemical substances. Bacteria and protozoans are inhibited by them. Beta-lactam and beta-lactamase inhibitors are two types of antibacterial agents that are commonly used to treat bacterial infections. In addition, they are employed to destroy or inhibit microbes from growing. Beta-lactam and beta-lactamase inhibitors are divided into five categories based on their molecular structure: combination, monobactam, carbapenem, cephalosporin, and penicillin.

Request Free Sample

Global Beta Lactam and Beta Lactamase Inhibitors Market: Growth Factors

The global beta-lactam and beta-lactamase inhibitors market is propelling at a significant rate. It is primarily being driven by higher demand in low & middle-income countries (LMICs) and an increase in the occurrence of infectious disorders. For instance, according to WHO, acute lower respiratory tract infections have been one of the leading causes of mortality and disability in both adults and children for decades. Lower respiratory tract infection is thought to account for about 4 million fatalities yearly and is the largest cause of mortality among children under the age of five.

Thus, to overcome such a huge burden of infectious diseases, the demand for beta-lactam and beta-lactamase inhibitors is on the rise thereby fostering market growth. Moreover, the market is being supplemented by the development of novel techniques for new beta-lactam and beta-lactamase inhibitors for fighting bacterial infection. In addition to this, the market’s expansion is being fueled by a huge number of clinical studies. However, the market for beta-lactam and beta-lactamase inhibitors is projected to be hampered by the development of antibiotic resistance and misuse as a result of over-the-counter availability. On the other hand, the global beta-lactam and beta-lactamase inhibitors market is expected to benefit from the identification of advanced promising compounds and innovative combination treatments during the forecast period.

The need for antibacterial drugs increased drastically during the COVID-19 period. Many governments allowed drug manufacturers to come up with immediate outcomes to halt the spread of the infection. As the COVID-19 infected person develops severe bacterial infections, there need for antibacterial agents doubles during the treatment. Also, other infectious diseases can cause severe problems to the patient already suffering from COVID-19. All these factors increased the demand for global beta lactam & beta lactamase inhibitor market.

Request Free Sample

Global Beta Lactam and Beta Lactamase Inhibitors Market: Segmentation

The global market for beta lactam & beta lactamase inhibitors is segregated based on drug class, route of administration, disease, and region.

The drug class segment of the global market is bifurcated based on carbapenem, penicillin, cephalosporin, monobactam, and combination.

Based on route of administration, the market is categorized into intravenous, oral, and others.

The disease segment of the market is divided into respiratory infection, urinary tract infection (apart from cUTI), skin infection, complicated intra-abdominal infections (cIAI), complicated urinary tract infection (cUTI), blood stream infection, nosocomial pneumonia, and others.

Beta Lactam and Beta Lactamase Inhibitors Market: Report Scope

Global Beta Lactam and Beta Lactamase Inhibitors Market: Regional Analysis

In 2020, Asia Pacific led the global beta-lactam and beta-lactamase inhibitors market in terms of revenue, and this trend is likely to continue during the forecast period. This is due to a spike in the frequency of chronic illnesses, growth in the elderly population, an increase in antibiotic usage, and the accessibility of over-the-counter medications without a prescription. Developing regions such as the Middle East, Latin America, and Africa are expected to offer lucrative growth opportunities to the market. Key factors such as no strict regulations or regulatory control to check over-the-counter drugs sale, easy accessibility of antibiotics without prescriptions, frequent outbreaks of infectious diseases, and the rising trend of self-medication may drive the demand of the market over the forecast period.

Global Beta Lactam and Beta Lactamase Inhibitors Market: Competitive Players

• Merck & Co. Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• Allergan Plc.
• Abbott Laboratories
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Pfizer Inc.
• Novartis International AG

are some of the key operating players in the global beta-lactam and beta-lactamase inhibitors market.

The Global Beta Lactam and Beta Lactamase Inhibitors Market is segmented as follows:

By drug class 

• carbapenem 
• penicillin
• cephalosporin
• monobactam
• combination

By route of administration 

• intravenous
• oral 
• and others 

By disease 

• respiratory infection 
• urinary tract infection (apart from cUTI) 
• skin infection 
• complicated intra-abdominal infections (cIAI)
• complicated urinary tract infection (cUTI)
• blood stream infection
• nosocomial pneumonia
• and others

Global Beta Lactam and Beta Lactamase Inhibitors Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.